Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial Meeting Abstract
| Authors: | Abou-Alfa, G.; Borbath, I.; Cohn, A.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D.; Roychowdhury, S.; Sadeghi, S.; Shroff, R.; Howland, M.; Li, A.; Cho, T.; Pande, A.; Javle, M. |
| Abstract Title: | Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial |
| Meeting Title: | ESMO 22nd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Jul 1-4 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-07-01 |
| Start Page: | S136 |
| End Page: | S137 |
| Language: | English |
| ACCESSION: | WOS:000558722000145 |
| DOI: | 10.1016/j.annonc.2020.04.226 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-144 -- Source: Wos |
